Description
Inclusion Criteria:
- 1. Age ≥18 years
- 2. Personal access to a computer and/or Smartphone for app download
- 3. Heart Failure (reduced and preserved ejection fraction) AND/OR
- 4. Atrial Fibrillation with CHA2DS2-VASc score greater than or equal to 2 in men and greater than or equal to 3 in women AND/OR
- 5. T2D and ASCVD, defined as follows:
- 1. Known CAD, prior ACS, or coronary artery revascularization
- 2. Prior TIA/stroke or known carotid or intracerebral atherosclerosis
- 3. Prior PAD including requiring revascularization
Exclusion Criteria:
- All patients
- 1. Current or anticipated participation in an interventional clinical trial of a drug/device
- 2. Currently receiving comfort care or enrolled in hospice
- 3. Life expectancy \<1 year
- 4. Pregnancy or active breastfeeding
- 5. Current or anticipated participation in an interventional clinical trial (other than TRANSFORM3 GDMT)
- 6. Patients without a clinical encounter within three years of study start date
- Heart Failure patients:
- 1. History of or plan for heart transplantation or left ventricular assist de-vice
- 2. Palliative chronic inotropic therapy
- 3. NYHA Class 4 heart failure
- Atrial Fibrillation patients:
- 1. Current prescription for OAC
- 2. Reversible cause of atrial fibrillation, such as post-cardiothoracic surgery or thyrotoxicosis
- 3. History of ischemic stroke in prior 7 days
- 4. Transient ischemic attack in prior 3 days
- 5. Platelet count \<70,000/ml
- 6. Hemoglobin concentration \<8g/dl
- 7. History of or condition associated with increased bleeding risk, such as hemophilia
- 8. Major surgical procedure or trauma within 14 days
- 9. Clinically significant gastrointestinal bleeding within 8 weeks
Ages Eligible for Study:
18 Years to N/A (ADULT, OLDER_ADULT)
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Yes